Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.98B
Market cap1.98B
Price-Earnings ratio
-4.74
Price-Earnings ratio-4.74
Dividend yield
Dividend yield
Average volume
1.39M
Average volume1.39M
High today
High today
Low today
Low today
Open price
$35.43
Open price$35.43
Volume
0.00
Volume0.00
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $33.81, with a market capitalization of 1.98B. The stock trades at a price-to-earnings (P/E) ratio of -4.74.

On 2026-04-09, Agios(AGIO) shares started trading at $35.43, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.39M.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

TipRanks 3d
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

JPMorgan raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $31 and keeps a Neutral rating on the shares. The firm updated the company’s...

Simply Wall St 5d
A Look At Agios Pharmaceuticals Valuation As It Pursues Accelerated FDA Approval For Mitapivat

Agios Pharmaceuticals (AGIO) is back on investors’ radar after the company moved to seek U.S. accelerated approval for mitapivat in sickle cell disease followin...

A Look At Agios Pharmaceuticals Valuation As It Pursues Accelerated FDA Approval For Mitapivat

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.